Alpha-synuclein single domain antibodies
AssigneeNew York University
InventorEinar M. SIGURDSSON
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to single domain antibodies that bind to α-synuclein and the use of these antibodies for the treatment and diagnosis of α-synucleinopathies. The present disclosure is also directed to polynucleotides encoding the α-synuclein single domain antibodies, therapeutic vectors comprising these polynucleotides and methods of administering these therapeutic vectors for the treatment of α-synucleinopathies.
Claims27
An anti-alpha-synuclein single-domain antibody or binding fragment thereof, said antibody or binding fragment thereof comprising a heavy chain variable region that comprises:
- a complementarity-determining region 1 (H-CDR1) comprising an amino acid sequence of any one of SEQ ID NOs:
- 33, 147, 151, or 218;
- a complementarity-determining region 2 (H-CDR2) comprising an amino acid sequence of any one of SEQ ID NOs:
- 69, 162, 166, or 219;
- and
- a complementarity-determining region 3 (H-CDR3) comprising an amino acid sequence of any one of SEQ ID NOs:
- 105, 177, 181, or 220.
-3. (canceled)
(canceled)
-12. (canceled)
-26. (canceled)
-36. (canceled)
-40. (canceled)
-45. (canceled)
Dependencies are inferred from the claim text.